On Air Now

Upcoming Shows

Program Schedule »


Listen Live Now » 1330 AM Sheboygan, WI


Current Conditions(Sheboygan,WI 53081)

More Weather »
79° Feels Like: 82°
Wind: NE 5 mph Past 24 hrs - Precip: 0”
Current Radar for Zip


Partly Cloudy 75°


Thunderstorms Early 65°


Cloudy 72°


Breaking News

State Senator Joe Leibham to not seek recount for last week's election

SHEBOYGAN, WI (WHBL) - Joe Leibham will not seek a recount for last week's 6th House District Republican primary. The Sheboygan state senator lost the four man race to State Senator Glenn Grothman by 219 votes, which was close enough to ask for a recount that would have been paid for by local government units. In a statement made Friday afternoon, Leibham said he has contacted Grothman about his decision and wished him well in the November general election.  He adds he is happy of the ...

Read More »

Isis to stop developing rheumatoid arthritis drug

(Reuters) - Isis Pharmaceuticals Inc said it will stop developing its experimental rheumatoid arthritis (RA) drug after a mid-stage trial showed the treatment failed to significantly improve the disease symptoms when compared to a placebo.

Patients treated with the drug, called ISIS-CRPRx, had some improvements in symptoms of RA but they were not statistically significant when compared to those of patients receiving a placebo.

The treatment was developed using Isis's "antisense" technology that helps a compound bind to a specific gene in order to interrupt the production of disease-causing proteins.

The company already has regulatory approval for another drug that uses the same technology to treat a rare genetic disorder causing dangerously high levels of "bad" LDL (low-density lipoprotein) cholesterol.

The drug, Kynamro, was approved by the FDA in January.

ISIS-CRPRx was aiming to treat RA by reducing the production of C-reactive protein (CRP) -- whose levels are dramatically elevated during inflammatory disorders.

The drug is also being tested in another mid-stage trial for the treatment of atrial fibrillation - a heart rhythm disorder. Data from the trial is expected in the first half of 2014, Isis said in a statement on Monday, adding that it would continue to test the drug in other diseases.

Isis shares closed at $29.23 on Friday on the Nasdaq.

(Reporting by Esha Dey in Bangalore, additional reporting by Zeba Siddiqui; Editing by Sreejiraj Eluvangal)